Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

An AI tool showed noninferiority to senior endocrinology physicians in insulin titration for hospitalized patients with type ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Patients with diabetes taking semaglutide had an absence of NAION risk at the 1-month, 3-month, 6-month, and 1-year time points after the index date. HealthDay News — For patients with diabetes ...

A new type of diabetes has been observed which is known to be caused due to chronic exposure to malnourishment during childhood and obesity. Type 5 diabetes has been observed to affect around 20 ...

Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide ... with type 2 diabetes and inadequate ...

The trial of the drug, orforglipron, measured its efficacy and safety in adults with Type 2 diabetes compared to ... of the injectable drugs we have now: Semaglutide. That is a big deal." ...